TrialFind
Saved trials

Filters

Status

Phase

Age group

TrialFind

Data sourced from ClinicalTrials.gov. Always consult a healthcare provider before enrolling.

PrivacyData sourcesRegulatory infoContact
Recruiting

A Longitudinal Study to Explore the Impact of Gut Microbiome on Brain Health in Alzheimer's Disease

Gut microbiota dysfunction is associated with Alzheimer's disease (AD). However, the potential modulatory mechanism remains unclear.

Jining, Shandong, ChinaView details
CompletedPhase 3

[18F]APN-1607 PET in Subjects With AD Compared to HC

The overall objective of this study is to compare the overall pattern of \[18F\]APN-1607 uptake in subjects with MCI, subjects with AD dementia, and healthy subjects.

Wuhan, Hubei, ChinaView details
CompletedPhase 2

A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease

The objective of this 3-month study is to assess the safety and efficacy of EHT 0202 in addition to acetylcholinesterase inhibitor in patients suffering from Alzheimer's Disease.

Ballainvilliers, France+21 moreView details
UnknownN/A

Couples Coping With Alzheimer's Disease

The purpose of this study is to test the efficacy of a new couples counseling intervention for people recently diagnosed with early Alzheimer's disease and their spouses. The study hypothesis is that counseling the couple shortly after the

New York, New York, United StatesView details
CompletedPhase 4

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

We are studying subjects with mild to moderate Alzheimer's disease who have been on a stable dose of any cholinesterase inhibitor \[donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne)\] for at least 3 months, and have not

Manhasset, New York, United StatesView details
CompletedPhase 2

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

This study will evaluate the performance characteristics of a novel \[18F\] amyloid detection ligand (18F\]-AV-45) with respect to its ability to distinguish patients with clinically-diagnosed probable Alzheimer's disease from cognitively n

Philadelphia, Pennsylvania, United StatesView details
CompletedPhase 2

Treatment of Alzheimer's Disease With CX516 (Ampalex)

Glutamate is an amino acid released by brain cells that acts to excite other cells. Glutamate attaches to special sites on cells called AMPA (alpha-amino-2,3-dihydro-5 methyl 3-oxo-4-isoxazolepropanoic acid) receptors.

Bethesda, Maryland, United StatesView details
CompletedPhase 3

Multicenter Vitamin E Trial in Aging Persons With Down Syndrome

The purpose of this study is to determine the safety and effectiveness of 2,000 international units of Vitamin E (alpha tocopherol)on cognitive function of aging persons with Down syndrome. It is a randomized, double-blind, placebo-controll

Multiple locationsView details
Withdrawn

Voice and Swallowing Disorders in Adults With and Without Alzheimer's Disease

This research study is investigating whether people with Alzheimer's disease experience more changes to voice and swallowing than their healthy age-matched peers. The prevalence of swallowing impairments in moderate-severe Alzheimer's Disea

Multiple locationsView details
CompletedPhase 1

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003

Hallandale, Florida, United States+20 moreView details
CompletedPhase 1

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

The primary objective of this exploratory imaging study is to further characterize \[18F\]T807, an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker indicative of neurodegeneration in conditions such as A

New Haven, Connecticut, United StatesView details
RecruitingN/A

Personalized Obstructive Sleep Apnea Treatment and Effects on Alzheimer's Disease Biomarkers and Cognition Among Blacks

The purpose of this research is to see how effective the Personalized obstructive sleep apnea (OSA) Treatment Adherence Model called PRAISE is in helping the patient stick to the physician recommended OSA treatment plan Positive Airway Pres

Miami, Florida, United StatesView details
TerminatedPhase 1

Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease

To investigate the brain receptor occupancy of idalopirdine in patients with Alzheimer's disease (AD)

Baltimore, Maryland, United StatesView details
CompletedN/A

Home-Based Assessment for Alzheimer Disease Prevention

The purpose of this study is to evaluate three methods of performing home-based assessments in Alzheimer's Disease (AD) prevention trials. The initial in-person assessment will be done in the clinic or at home.

Birmingham, Alabama, United States+27 moreView details
Completed

Down Syndrome Biomarker Initiative (DSBI)

Non-randomized natural history study involving 12 subjects with Down Syndrome, who are aged 30-60 years old. This study will observe 3 different groups: four non-demented subjects between ages 30-40 years old, four non-demented subjects bet

La Jolla, California, United StatesView details
WithdrawnPhase 1

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

This is a study to evaluate the brain metabolic response using Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), safety, tolerability and pharmacokinetics of AGN-242071 in patients with mild to moderate Alzheimer's Disease on a sta

Costa Mesa, California, United States+5 moreView details
RecruitingN/A

Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia

The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.

Incheon, Bupyeong 6(yuk)-dong, Bupyeong-gu, South Korea+10 moreView details
UnknownN/A

Education of Caregivers of Alzheimer's Patients

Purpose of the Research: This study will be conducted to determine the effect of the education given to caregivers of Alzheimer's patients registered to home health services on their knowledge and attitudes towards Alzheimer's disease. Hypo

Ordu, Cumhuriyet Campus, Turkey (Türkiye)View details
CompletedPhase 4

Side Effects of Newer Antipsychotics in Older Adults

This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals.

San Diego, California, United StatesView details
CompletedPhase 1 / Phase 2

Effect of Panax Ginseng on the Cognitive Performance in Alzheimer's Disease

We investigate the clinical efficacy of Panax ginseng in Alzheimer's disease (AD).

Multiple locationsView details
Load more trials